Lucid Capital initiated coverage of Cybin (CYBN) with a Buy rating and $106 price target Cybin is developing alternative formulations and derivatives of psychedelic drugs, the analyst tells investors in a research note. The firm points out the Drug Enforcement Agency classifies both of Cybin’s drugs as Schedule I, meaning “drugs with no currently accepted medical use and high potential for abuse.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Psychedelic: atai, Beckly Psytech to combine in all-share transaction
- Cybin Secures U.S. Patent for CYB004 Program in Anxiety Disorder Treatment
- Cybin announces additional U.S. patent supporting CYB004
- Cybin CEO to Discuss Strategic Advances at Upcoming Fireside Chat
- Cybin Supports FDA’s Push for Psychedelic Research